For Better user experience please view the website in portrait Mode


CellMax Life Achieves CLIA Certification & CAP Accreditation for Precision Cancer Testing Laboratories

Nov 03, 2016

CellMax Life receives CLIA Certification in the U.S. and CAP Accreditation in Taiwan for its cancer testing laboratories

SUNNYVALE, CA AND TAIPEI CITY, TAIWAN (PRWEB) OCTOBER 18, 2016 – CellMax Life announced today the company has received certification under the Clinical Laboratory Improvement Amendments (CLIA). The company also announced it has received notice of accreditation from the College of American Pathologists (CAP) for its Taipei laboratory.

CLIA regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. To gain the CLIA certification, CellMax had to meet quality standards for proficiency testing, management of patient testing, personnel qualifications, quality control, and quality assurance.

CAP accreditation is an internationally recognized standard of operational excellence. It is recognized by the United States government as being equally or more stringent than the federal inspection program, and is specifically designed to ensure the highest standard of care for all laboratory samples.

“We are committed to reducing cancer mortality by making affordable, non-invasive early cancer detection easily accessible globally to everyone,” said Atul Sharan, President and CEO of CellMax Life. “These clinical laboratories certifications, along with our breakthrough proprietary CTC CMx platform, pave the way for our next growth phase in the United States, and give us a unique springboard into China and India.”

About CellMax Life

CellMax Life, Inc. is a precision cancer blood-testing company providing comprehensive, personalized multi-biomarker technology platforms for genetic cancer risk assessment, early detection and personalized treatment of cancer. CellMax Life’s flagship product is CellMax CRC-Protect, a multi-biomarker blood test based on their proprietary CTC CMx platform for early detection of colorectal cancer, which is currently marketed in Taiwan. CellMax Life has CLIA certification and CAP accreditation for its United States and Taiwan laboratories, respectively. For more information, please visit,, or call +1 650-564-3905 (U.S.), or (+886) 0800-555-885 (Taiwan). Offices are at: 1271 Oakmead Parkway, Sunnyvale, CA 94085 and 18F-1 Park Street, Nangkang, Taipei City.